Literature DB >> 2709661

Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats.

B L Kasiske1, M P O'Donnell, M P Cleary, W F Keane.   

Abstract

Increasing evidence from experimental models of chronic renal failure suggests that abnormalities in lipid metabolism may contribute to progressive renal injury. In the present study, hyperlipidemic obese, and normolipemic lean Zucker rats were subjected to unilateral nephrectomy or sham surgery at eight weeks of age. After 32 weeks, renal injury was greater in obese than in lean rats, and injury was made worse by nephrectomy. Among the major lipid classes, increased renal cortical cholesteryl esters were positively correlated with the degree of renal injury, suggesting that mechanisms analogous to those thought to be important in the pathogenesis of atherosclerosis may cause renal injury. Among phospholipid fatty acids, the ratio of oleic to linoleic acids (18:1/18:2) was strongly linked to both glomerular (r = 0.83, P less than 0.01) and tubulo-interstitial (rr = 0.80, P less than 0.01) injury, suggesting a possible role for a relative essential fatty acid deficiency in renal injury. There were also strong, negative associations between eicosapentaenoic acid levels and glomerular (r = -0.63, P less than 0.01) and tubulointerstitial (r = -0.71, P less than .01) injury. Altogether, these results suggest that specific abnormalities in renal lipid metabolism may be important in the pathogenesis of chronic, progressive renal injury.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2709661     DOI: 10.1038/ki.1989.6

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

1.  Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.

Authors:  E Hommel; P Andersen; M A Gall; F Nielsen; B Jensen; P Rossing; J Dyerberg; H H Parving
Journal:  Diabetologia       Date:  1992-05       Impact factor: 10.122

2.  Residual renal function after partial or radical nephrectomy for renal cell carcinoma.

Authors:  David Chapman; Ron Moore; Scott Klarenbach; Branko Braam
Journal:  Can Urol Assoc J       Date:  2010-10       Impact factor: 1.862

3.  Rosiglitazone, peroxisome proliferator receptor-gamma agonist, ameliorates gentamicin-induced nephrotoxicity in rats.

Authors:  Emin Ozbek; Yusuf Ozlem Ilbey; Abdulmuttalip Simsek; Mustafa Cekmen; Fatih Mete; Adnan Somay
Journal:  Int Urol Nephrol       Date:  2009-09-25       Impact factor: 2.370

4.  The combination of lovastatin and enalapril in a model of progressive renal disease.

Authors:  B H Brouhard; H Takamori; S Satoh; S Inman; M Cressman; K Irwin; V Berkley; N Stowe
Journal:  Pediatr Nephrol       Date:  1994-08       Impact factor: 3.714

5.  Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study.

Authors:  Mahboob Rahman; Wei Yang; Sanjeev Akkina; Arnold Alper; Amanda Hyre Anderson; Lawrence J Appel; Jiang He; Dominic S Raj; Jeffrey Schelling; Louise Strauss; Valerie Teal; Daniel J Rader
Journal:  Clin J Am Soc Nephrol       Date:  2014-05-15       Impact factor: 8.237

6.  Sesamin Ameliorates High-Fat Diet-Induced Dyslipidemia and Kidney Injury by Reducing Oxidative Stress.

Authors:  Ruijuan Zhang; Yan Yu; Jianjun Deng; Chao Zhang; Jinghua Zhang; Yue Cheng; Xiaoqin Luo; Bei Han; Haixia Yang
Journal:  Nutrients       Date:  2016-05-09       Impact factor: 5.717

7.  Relieving lipid accumulation through UCP1 suppresses the progression of acute kidney injury by promoting the AMPK/ULK1/autophagy pathway.

Authors:  Wei Xiong; Zhiyong Xiong; Anni Song; Chuntao Lei; Chen Ye; Chun Zhang
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

8.  Effects of unilateral nephrectomy on renal function in male Spontaneously Diabetic Torii fatty rats: a novel obese type 2 diabetic model.

Authors:  Yoshiaki Katsuda; Yusuke Kemmochi; Mimi Maki; Ryuhei Sano; Yasufumi Toriniwa; Yukihito Ishii; Katsuhiro Miyajima; Kochi Kakimoto; Takeshi Ohta
Journal:  J Diabetes Res       Date:  2014-08-10       Impact factor: 4.011

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.